COX‐2 NSAIDs showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
It is very uncertain whether SSRIs or SNRIs changes withdrawals due to adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether testosterone changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).